Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyFidelis Care Tocilizumab Prior Auth Coverage | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFidelis CarePolicy N/A

    Tocilizumab (Actemra/Tyenne) prior authorization and coverage criteria

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, clinical criteria, prescriber and age restrictions, and continuation requirements for Actemra/Tyenne subcutaneous products for Fidelis Care members in North Carolina.

    Policy Summary
    PayerFidelis Care
    PolicyTocilizumab (Actemra/Tyenne) prior authorization and coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionPrior authorization requires documentation of diagnosis, prior medication trials as specified per indication, appropriate prescriber, and demonstration of response for continuation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4products listed for Actemra/Tyenne formulations
    end of plan yearstandard coverage duration for approvals
    response requiredcontinuation therapy requirement
    age minimums specifiedage restrictions present

    Coverage Criteria and Clinical Requirements

    Coverage Criteria — General Requirements

    Covered when ALL of the following are met:

    ALL of the following

    • Request is for initial or continuation therapy for a medication listed in the plan's specialty/oncology/drug-specific criteria (see product-specific criteria within this Coverage Criteria section).

      Operative: refer to product-specific criteria groups for detailed requirements.

    • Documentation includes diagnosis, relevant prior therapies (including specific agents and duration where required), and prescriber specialty or consultation notes when a specialist is required.
    • Concurrent use exclusions are respected: no concurrent use with other biologic DMARDs or targeted synthetic DMARDs unless explicitly allowed in the product-specific criteria; no concurrent use of two agents within the same biologic class unless allowed; some agents also exclude use with specific named products (e.g., Benlysta with Lupkynis).
    • For oncology and targeted agents, tumor molecular testing results (e.g., EGFR, BRAF V600, KRAS G12C, ALK, ROS1, RET) or other biomarker evidence required by the product's FDA label or the plan's product-specific criteria must be provided.

    Codes, Age Limits and Numeric Thresholds

    Prior Authorization, Documentation and Step Therapy

    Prior Authorization

    Prior authorization requirements

    Prior authorization requires documentation of diagnosis, prior medication trials as specified per indication, appropriate prescriber (see prescriber restrictions), and that continuation requests document clinical response; approvals are through the end of the plan year.

    • Submit diagnosis, concurrent medications, and prior drugs tried.
    • Continuation requests must document that the patient had a response to therapy.
    Prior Authorization

    Benlysta prior authorization

    Benlysta (belimumab) requires prior authorization. For SLE initial therapy the patient must have autoantibody‑positive SLE (positive ANA and/or anti‑dsDNA) and Benlysta must be used concurrently with at least one other standard therapy unless the patient is intolerant; continuation requires documented response to Benlysta and concurrent use with at least one standard therapy.

    • Age restriction: 5 years and older for initial SLE therapy.
    • Prescriber: rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist (initial and continuation); lupus nephritis requires nephrologist or rheumatologist involvement.

    Background and Scope

    Tocilizumab (Actemra/Tyenne) is indicated for multiple inflammatory rheumatologic conditions including rheumatoid arthritis and polyarticular juvenile idiopathic arthritis. The policy separates initial and continuation therapy requirements and emphasizes prescriber specialty and documentation of prior therapies where specified; continuation approvals require documentation that the patient had a response to therapy and authorizations are typically approved through the end of the plan year.

    Definitions and Clinical Terms

    patient had a response to therapy — Continuation therapy
    Continuation criterionPatient had a response to therapy (documented benefit)
    Authorization durationApproved through end of plan year when continuation criteria met
    ApplicationApplies across listed products for continuation requests
    autoantibody-positive SLE — definition for Benlysta criteria
    DefinitionSLE defined as positive for antinuclear antibodies (ANA) and/or anti‑double‑stranded DNA (anti‑dsDNA)
    Benlysta requirementAutoantibody‑positive SLE required for Benlysta initial therapy

    Revision History

    2024-?status_note

    Several products were marked 'UNDER CMS REVIEW' for exclusions, required information, age, prescriber restrictions, coverage duration, and other criteria; specific product examples include sofosbuvir-velpatasvir and Somavert.

    2024-?status_noteLatest

    Stivarga listed as 'UNDER CMS REVIEW' for exclusion, required information, age, prescriber restrictions, coverage duration, other criteria and indications.

    Policy Summary
    PayerFidelis Care
    PolicyTocilizumab (Actemra/Tyenne) prior authorization and coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionPrior authorization requires documentation of diagnosis, prior medication trials as specified per indication, appropriate prescriber, and demonstration of response for continuation.
    SourceLink
    On This Page
    Coverage Criteria and Clinical RequirementsCodes, Age Limits and Numeric ThresholdsPrior Authorization, Documentation and Step TherapyBackground and ScopeDefinitions and Clinical TermsRevision History
  1. For transplant- or infectious disease–related specialty agents (e.g., Livtencity for CMV), documentation of transplant status, CMV infection confirmation, and failure or intolerance to preferred therapies when indicated must be provided.
  2. For hematologic supportive agents (e.g., Retacrit and other ESAs, IVIG products including Bivigam/others), indicate indication (e.g., anemia of chronic kidney disease, chemotherapy-induced anemia with current chemotherapy), hemoglobin/iron studies, transfusion history, and prior therapies tried per product-specific criteria.
  3. Age and prescriber restrictions per product apply (examples: pediatric age minimums for many biologics; neurologist for MS agents; oncologist for oncology agents; pulmonologist/cardiologist for PAH agents).
  4. Continuation approvals require documentation of clinical benefit from prior authorization period (e.g., symptom improvement, objective measures, lab or imaging response) and ongoing adherence to concurrent therapies when required.
  5. inv-02: Benlysta — SLE initial therapy

    Benlysta (belimumab) — Systemic lupus erythematosus (SLE) initial therapy

    ALL of the following

    • Diagnosis of autoantibody-positive SLE (positive ANA and/or anti-dsDNA).
    • Patient is 5 years of age or older for initial therapy.
    • Benlysta will be used concurrently with at least one other standard therapy unless the patient is intolerant to all standard therapies (examples: antimalarials, systemic corticosteroids, azathioprine, mycophenolate mofetil, methotrexate).
    • Prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist (initial and continuation); lupus nephritis requires nephrologist or rheumatologist involvement.
    • Exclude concurrent use with other biologics or with Lupkynis unless specifically allowed by sponsor guidance.
    • Initial authorization duration: SLE initial 4 months; lupus nephritis initial 6 months. Continuation: SLE cont 1 year; lupus nephritis cont 1 year, contingent on documented clinical response to therapy.

    inv-03: Benlysta — Lupus nephritis

    Benlysta — Lupus nephritis

    ALL of the following

    • Diagnosis of lupus nephritis confirmed by appropriate clinical and laboratory assessment.
    • Benlysta is being used concurrently with an immunosuppressive regimen (examples: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or systemic corticosteroid).
    • Prescribed by or in consultation with a nephrologist or rheumatologist (initial and continuation).
    • Patient has demonstrated clinical response to Benlysta (for continuation) and concurrent immunosuppressive therapy.
    • Initial authorization duration: 6 months; continuation 1 year when benefit demonstrated.

    inv-04: Cosentyx — Initial therapy criteria (selected indications)

    Cosentyx (secukinumab) — Initial therapy (selected indications)

    ALL of the following

    • Diagnosis and relevant prior medication history documented.
    • Exclusion: concurrent use with other biologics or targeted synthetic DMARDs is not allowed.
    • Indication-specific requirements: for plaque psoriasis, patient has tried at least one traditional systemic agent (e.g., methotrexate, cyclosporine, acitretin, PUVA) for at least 3 months unless intolerant, or has contraindication to methotrexate; for hidradenitis suppurativa, tried at least one other therapy (e.g., systemic antibiotics, isotretinoin); for non-radiographic axial spondyloarthritis require elevated CRP or sacroiliitis on MRI as specified.
    • Prescriber specialty requirements apply for initial therapy (eg, dermatology, rheumatology depending on indication).
    • Continuation: patient has experienced benefit from therapy (see continuation group).

    inv-05: Cosentyx — Continuation

    Cosentyx — Continuation

    ALL of the following

    • Patient has demonstrated clinical benefit from Cosentyx (improvement in signs/symptoms or objective measures appropriate to the indication).
    • No concurrent use with other biologic or targeted synthetic DMARDs unless permitted by product-specific guidance.
    • Authorization may be through end of plan year when benefit is documented.

    inv-06: Ambrisentan/Bosentan — PAH

    Ambrisentan / Bosentan — Pulmonary arterial hypertension (PAH)

    ALL of the following

    • Diagnosis of WHO Group 1 pulmonary arterial hypertension confirmed by right-heart catheterization.
    • Prescribed by or in consultation with a cardiologist or pulmonologist.
    • For CTEPH (bosentan) patient must have tried Adempas, have a contraindication to Adempas, or be currently receiving bosentan for CTEPH per Other Criteria requirements.
    • Authorization duration: typically 1 year.

    inv-07: Haegarda — HAE prophylaxis continuation

    Haegarda — Hereditary angioedema (HAE) prophylaxis continuation

    ALL of the following

    • Diagnosis of HAE Type I or II confirmed by low functional C1-INH (<50% of normal) and low C4 levels at baseline; for HAE with normal C1-INH meet genetic or family-history criteria or refractory to high-dose antihistamines as specified.
    • Prescribed by or in consultation with an allergist/immunologist or HAE specialist.
    • Continuation approval requires prescriber statement that patient has had a favorable clinical response to Haegarda prophylaxis compared with baseline.

    inv-08: Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

    Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL)

    ALL of the following

    • Patient is 18 years or older and diagnosis of CLL or SLL is documented.
    • Patient has tried at least one prior systemic regimen (examples include ibrutinib, venetoclax, rituximab, obinutuzumab, chlorambucil, fludarabine, cyclophosphamide, bendamustine, high-dose methylprednisolone, alemtuzumab, acalabrutinib, zanubrutinib, ofatumumab) as applicable to the requested agent's criteria.
    • Prescribed by or in consultation with an oncologist/hematologist.

    inv-09: Cosentyx (secukinumab) — Initial and Continuation Therapy

    Cosentyx — Initial and Continuation Therapy (summary)

    ALL of the following

    • See inv-04 and inv-05 for indication-specific initial and continuation requirements.
    • Exclusion: concurrent use with other biologics or targeted synthetic DMARDs.
    • Age and prescriber restrictions apply by indication; typical authorization through end of plan year for continuation when benefit documented.

    inv-10: Targeted therapy with BRAF V600 mutation requirement

    Targeted therapy requiring BRAF V600 mutation (selected agents)

    ALL of the following

    • For agents used to treat BRAF V600–mutated malignancies (e.g., Zelboraf in combination, Cotellic combinations), documentation of tumor testing positive for BRAF V600 mutation is required prior to authorization unless the product-specific criteria state otherwise.
    • When used in CNS or other off-label indications as listed, meet the product-specific combination and indication requirements (e.g., combination with vemurafenib for melanoma with brain metastases).

    inv-11: Cresemba (isavuconazole) — fungal indications

    Cresemba (isavuconazole) — fungal indications

    ALL of the following

    • Diagnosis and relevant microbiology/imaging supporting invasive fungal infection, or indication-specific evidence (e.g., mucormycosis, invasive aspergillosis).
    • Prescribed by or in consultation with an infectious disease specialist when appropriate; authorization duration commonly 3 months unless otherwise indicated.

    inv-12: Dalfampridine — multiple sclerosis ambulatory improvement

    Dalfampridine — improvement in ambulation for multiple sclerosis

    ALL of the following

    • Patient has a diagnosis of multiple sclerosis and is ambulatory with objective impairment in walking documented (e.g., timed 25-foot walk or MSWS-12).
    • Prescribed by or in consultation with a neurologist or MS specialist for initial and continuation therapy.
    • Initial authorization 4 months; continuation 1 year, contingent on documented benefit.

    inv-19: Dupixent (dupilumab) — multiple indications

    Dupixent (dupilumab) — multiple indications (initial and continuation highlights)

    ALL of the following

    • Concurrent use with other biologics (e.g., anti-IL monoclonals like Fasenra, Nucala, Xolair) or JAK inhibitors is excluded unless specified otherwise.
    • Indication- and age-specific initial requirements apply (examples: AD — prior topical CS trial; asthma — eosinophil thresholds and maintenance inhaler therapy; CRSwNP — prior surgeries or oral steroid courses).
    • Continuation requires demonstrated benefit and adherence to concomitant required therapies (e.g., intranasal corticosteroids for CRSwNP).

    inv-20: Elrexfio — multiple myeloma

    Elrexfio — multiple myeloma

    ALL of the following

    • Prescribed by or in consultation with an oncologist; patient is 18 years or older.
    • Patient has tried at least four prior systemic regimens and among previous regimens received at least one drug from each class: a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody, per FDA labeling for later-line therapy.

    inv-21: Emgality (galcanezumab) — migraine and episodic cluster headache

    Emgality (galcanezumab) — migraine prevention and episodic cluster headache

    ALL of the following

    • Migraine prevention: patient has ≥4 migraine headache days per month prior to initiating Emgality, or if currently taking Emgality, has significant clinical benefit (e.g., reduction in migraine days).
    • Episodic cluster headache: patient meets frequency criteria (one headache every other day to eight headaches per day).

    inv-22: Enbrel (etanercept) — rheumatologic and dermatologic indications

    Enbrel (etanercept) — rheumatologic and dermatologic indications

    ALL of the following

    • Exclusion: concurrent use with other biologic therapy or targeted synthetic DMARDs is not allowed.
    • Initial therapy requirements: RA — tried one conventional synthetic DMARD for ≥3 months; JIA/JRA — aggressive disease or prior systemic therapy or contraindication to MTX; plaque psoriasis — tried at least one traditional systemic agent ≥3 months unless intolerant.
    • Continuation: evidence of response to therapy required for ongoing approval.

    inv-23: Epidiolex (cannabidiol) — pediatric seizure disorders and TSC

    Epidiolex (cannabidiol) — pediatric seizure disorders and TSC

    ALL of the following

    • Prescribed by or in consultation with a neurologist for initial therapy; age and syndrome-specific prior therapy trials required (examples: Dravet — tried or receiving ≥2 other antiseizure drugs or clobazam/Diacomit/Fintepla; LGS/TSC — tried or receiving ≥2 other antiseizure drugs).
    • Continuation requires demonstration of response to therapy.

    inv-103 / inv-104 / inv-128: COVERAGE CRITERIA — Concurrent use and continuation rules

    General coverage considerations and notable exclusions

    ALL of the following

    • Concurrent use of multiple biologic DMARDs or targeted synthetic DMARDs is generally excluded across products unless a product-specific criterion allows it (see individual drug entries).

      inv-103 and inv-104: concurrent use exclusions apply.

    • Continuation without demonstrated patient benefit is not covered; continuation approvals require objective or prescriber-documented benefit (symptoms, labs, imaging, functional measures).

      inv-128

    • Some products exclude or require avoidance with potent CYP3A4 inhibitors or other drug interaction concerns (example: dihydroergotamine with potent CYP3A4 inhibitors).
    • Product-specific age, prescriber, diagnostic test, and prior-therapy requirements must be followed. Failure to provide required documentation may result in denial or delay of authorization.
    Prior Authorization

    Cosentyx prior authorization

    Cosentyx (secukinumab) requires prior authorization with documentation of diagnosis and prior medication trials; initial therapy rules and age limits vary by indication and prescriber specialty restrictions apply. Continuation requires documented patient benefit and concurrent use with other biologics or targeted synthetic DMARDs is excluded.

    • Plaque psoriasis initial: trial of ≥1 traditional systemic agent ≥3 months (or a non‑Cosentyx biologic counts) or contraindication to methotrexate.
    • Hidradenitis suppurativa initial: tried at least one other therapy (e.g., systemic antibiotics, isotretinoin).
    • Prescriber restrictions: dermatology or rheumatology depending on indication; age limits per indication (examples: PP ≥6 years, HS ≥18 years).
    Prior Authorization

    Prior Authorization Requirement

    Prior authorization is required for listed products and must include documentation of diagnosis, prior treatment trials as specified, prescriber specialty when required, and objective measures where indicated; approvals are commonly limited to specified durations (e.g., up to 1 year or plan year).

    • Provide diagnosis, prior medication history (including specific therapies tried), and relevant lab/genetic or objective test results when requested.
    • Prescriber specialty documentation required when specified (e.g., neurologist for MS agents, pulmonologist for ILD/PAH).
    Prior Authorization

    Fasenra initial therapy requirements

    For initial Fasenra therapy in asthma, prior authorization requires a blood eosinophil count ≥150 cells/µL within the prior 6 weeks, prior use of an inhaled corticosteroid plus at least one additional controller, and documentation of uncontrolled asthma (exacerbations, ED/hospital visits, reduced FEV1 or FEV1/FVC, or worsening with steroid taper).

    • Age and prescriber limits: asthma initial—6 years and older; prescribed by or in consultation with an allergist, immunologist, or pulmonologist.
    • Continuation requires evidence the patient has responded to therapy and continues ICS.
    Prior Authorization

    Exkivity prior authorization

    Exkivity prior authorization requires that the patient has locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation as determined by an approved test, and that the patient previously tried at least one platinum‑based chemotherapy.

    • Document mutation status from an approved test and prior platinum‑based chemotherapy trial.
    Prior Authorization

    ESA/Retacrit prior authorization

    Retacrit and other erythropoiesis‑stimulating agents require prior authorization with indication‑specific hemoglobin thresholds and prior therapy criteria; prescriber specialty requirements apply for MDS or myelofibrosis.

    • Examples: CKD (not on dialysis) initial therapy if Hb <10.0 g/dL (adults) or ≤11 g/dL (children); continuation if Hb ≤12 g/dL.
    • For chemotherapy‑induced anemia approve if patient is receiving myelosuppressive chemotherapy and Hb ≤12.0 g/dL.
    Prior Authorization

    General prior authorization requirement

    Prior authorization is required for many listed specialty drugs and must include documentation of diagnosis, age, prescriber specialty when specified, and any product‑specific criteria; authorization durations are typically 1 year or as specified per product.

    • Provide required clinical information demonstrating the member meets the listed diagnostic, biomarker, prior therapy, age, prescriber, and combination‑therapy criteria.
    • Authorizations are commonly approved through the end of the plan year or for 12 months when noted.
    Prior Authorization

    Omnitrope prior authorization

    When Omnitrope criteria are met, authorization will be issued for 12 months.

    • Ensure submission includes diagnosis and any required growth‑hormone testing results as specified in product criteria.
    Prior Authorization

    Authorization duration and requirement

    Prior authorization is required for most products and, where specified, will be authorized for up to 1 year; some indications have shorter initial authorization durations (examples: onychomycosis, ivermectin 30 days, Livtencity 2 months for treatment).

    • Check product entry for indication‑specific authorization lengths (e.g., 4 months initial for some biologics, 6 months for certain induction regimens).
    Note

    Part B vs Part D determination

    Some products require a Part B versus Part D determination at prior authorization review per CMS guidance; the policy notes that certain agents (e.g., lapatinib) include a Part B prerequisite determination.

    • If applicable, document the Part B prerequisite status so the PA reviewer can determine benefit routing.
    Prior Authorization

    Long-acting opioid PA

    Long‑acting opioids require annual prior authorization and documentation that the patient is not opioid‑naive, that non‑opioid therapies have been tried, PDMP check completed, risks and benefits discussed, and a documented treatment plan with scheduled reassessments.

    • Patients with cancer, in hospice, sickle cell disease, or in long‑term care are exempt from some criteria.
    • Confirm indication is chronic/intractable pain prior to quantity exception reviews.
    Prior Authorization

    Livtencity PA

    Livtencity prior authorization requires that the patient weighs ≥35 kg, is post‑transplant (HSCT or solid organ), and has CMV infection/disease refractory to at least one of cidofovir, foscarnet, ganciclovir or valganciclovir or has significant intolerance to ganciclovir/valganciclovir.

    • Document weight, transplant status, and prior antiviral therapy or intolerance.
    Prior Authorization

    Lapatinib PA

    Lapatinib prior authorization approves use for HER2‑positive recurrent/metastatic breast cancer when used with capecitabine or trastuzumab after at least two prior anti‑HER2 regimens, or when used with an aromatase inhibitor in appropriate HR+ patients per menopausal/ovarian suppression rules.

    • Document metastatic disease status, HER2 and hormone receptor status, and prior anti‑HER2 regimen history.
    • Note: Part B before Part D step therapy applies to MA‑PD beneficiaries per the lapatinib entry.
    Prior Authorization

    Prior authorization required for listed specialty drugs

    Prior authorization for specialty drugs requires documentation of indication, mutation/test status (e.g., BRAF V600), prescriber specialty when specified, and prior therapies where indicated; approvals are commonly limited to defined durations (commonly 12 months or 1 year).

    • Include molecular testing reports and prior systemic therapy history when applicable.
    • Follow product‑specific prescriber specialty requirements.
    Prior Authorization

    Odomzo prior authorization

    Odomzo prior authorization requires diagnosis and indication‑specific criteria; coverage durations vary by indication (example: 3 months for enterocutaneous fistula/diarrhea associated with chemotherapy; 1 year for most other indications).

    • Document grade of diarrhea and prior antimotility therapy for chemotherapy‑associated diarrhea when applicable.
    Prior Authorization

    Otezla prior authorization

    Otezla prior authorization requires documentation of prior systemic agents (or contraindication) and response for initial therapy and continuation; initial plaque psoriasis typically requires trial of at least one traditional systemic agent for ≥3 months unless intolerant.

    • Document prior systemic agent trials, reason for intolerance or contraindication if applicable, and evidence of response for continuation.
    • Prescriber specialty requirements apply for initial therapy in some indications.
    Prior Authorization

    Ofev prior authorization

    Ofev (nintedanib) prior authorization requires diagnosis confirmation (HRCT or surgical biopsy for IPF) and forced vital capacity (FVC) thresholds for initiation and continuation (e.g., IPF FVC ≥40% predicted; chronic fibrosing ILD initial FVC ≥45% predicted).

    • Ensure HRCT or surgical lung biopsy reports and FVC percent predicted are submitted.
    • Prescriber: pulmonologist or consult with pulmonologist/rheumatologist where specified.
    Prior Authorization

    Lipid-lowering agents: LDL and trial requirements

    Lipid‑lowering therapy prior authorization requires documentation of LDL‑C thresholds, phenotypic confirmation or diagnostic scoring (HeFH/HoFH) and trials of high‑intensity statins or documented statin intolerance prior to approval.

    • Provide lipid panel results, evidence of prior statin therapy and response, and phenotypic or genetic confirmation where required (e.g., Dutch Lipid Network score).
    Prior Authorization

    Radicava ORS prior authorization

    Radicava ORS initial approval requires a definite or probable ALS diagnosis per El Escorial (or revised Airlie House) criteria, ALSFRS‑R item scores of ≥2 on each item, adequate respiratory function per prescriber, and prior or current riluzole therapy.

    • Submit ALS diagnostic documentation, ALSFRS‑R scores, respiratory assessment, and evidence of riluzole trial or use.
    Prior Authorization

    Rinvoq indication-specific prior auth

    Rinvoq prior authorization is indication‑specific; initial therapy generally requires prior trials such as one TNFi for RA/PsA (or intolerance), a 90‑day trial of at least one systemic therapy for atopic dermatitis, and objective inflammation plus a 3‑month TNFi trial for non‑radiographic axial spondyloarthritis.

    • Document prior biologic or conventional therapy trials and reason for intolerance if applicable.
    • Continuation requires documented response to therapy.
    Prior Authorization

    Prior authorization required

    Prior authorization is required for listed products; reviewers will verify diagnosis, age, prescriber specialty, mutation/test status, and prior therapies where applicable; coverage durations are commonly 1 year unless otherwise specified.

    • Prepare to submit all required diagnostic, biomarker, and prior therapy documentation to support approval.
    Prior Authorization

    NSCLC – EGFR-targeted agents

    NSCLC EGFR‑targeted agents require prior authorization with documentation of diagnosis, EGFR mutation testing results from an approved test, and prior therapies as specified by the NSCLC EGFR criteria (e.g., T790M requires prior EGFR TKI exposure).

    • Attach approved test reports showing specific EGFR mutations (examples: exon 19 deletions, exon 21 L858R, T790M where applicable).
    • Document prior EGFR TKI therapy and disease status per the product entry.
    Prior Authorization

    Tremfya prior authorization

    Tremfya prior authorization requires evidence of prior systemic therapy (or documented intolerance) for plaque psoriasis and specialist involvement (dermatologist consultation or prescribing) for initiation; continuation requires documented response to therapy.

    • Document prior conventional systemic therapy trials or reason for intolerance; for UC induction provide dosing/induction documentation and corticosteroid status.
    Prior Authorization

    Prior authorization required for listed specialty drugs

    Prior authorization is required for specialty drugs and will be approved only when submitted clinical information demonstrates the member meets the listed diagnostic, biomarker, prior therapy, age, prescriber, and combination‑therapy criteria specific to the product.

    • Failure to provide required documentation (diagnosis, labs, mutation status, prior therapy history) may result in denial.
    • Follow the product‑specific checklist in the policy when submitting PA requests.
    Prior Authorization

    Prior authorization and prescriber requirements

    Prior authorization requests must include supporting diagnosis, age, prescriber specialty, and documentation of prior therapy trials as specified for each drug and indication (examples: specialist prescriber for pouchitis or asthma biologics requiring allergist/immunologist/pulmonologist consultation).

    • For indications requiring specialist input, include the specialist consultation note or prescribing provider credentials.
    • Include objective test results when required (e.g., breath test for SIBO, biopsy results, mutation test reports).
    Step Therapy

    Step therapy trials required

    For rheumatoid arthritis and polyarticular JIA, step therapy typically requires trials of two specified biologic or targeted agents (or qualifying exceptions such as heart failure or prior lymphoproliferative disorder); providers must document prior biologic/targeted agent trials or the applicable exception.

    • List prior biologic/targeted therapies tried and durations per the RA/PJIA initial therapy rules.
    • Document any contraindications or exceptions that would bypass step therapy.
    Step Therapy

    Cosentyx step therapy

    For plaque psoriasis initial therapy with Cosentyx, the patient must have tried at least one traditional systemic agent for ≥3 months (or have a contraindication); a prior biologic that is not Cosentyx counts as a trial.

    • Document the traditional systemic agent trial and duration or reason for contraindication.
    • If a prior biologic was used, specify agent and dates of therapy.
    Step Therapy

    HS step therapy

    For hidradenitis suppurativa initial therapy with Cosentyx, prior authorization requires documentation that the patient tried at least one other therapy (e.g., systemic antibiotics or isotretinoin).

    • Provide records of prior antibiotic or isotretinoin therapy and response or intolerance.
    Step Therapy

    Step Therapy/Required Prior Trials

    Many agents require trials of at least one alternative or conventional therapy before approval; providers must document prior medication trials (examples include trials of systemic antibiotics for HS, traditional systemic agents for plaque psoriasis, midodrine before droxidopa, or at least one conventional synthetic DMARD for RA).

    • Include medication names, treatment durations, and reasons for discontinuation or intolerance where applicable.
    • Failure to document required prior trials may result in denial.
    Step Therapy

    Firmagon step requirement

    Firmagon prior authorization requires that patients new to therapy try Eligard or Orgovyx prior to approval of Firmagon.

    • Document prior trial of Eligard or Orgovyx or provide rationale for inability to try these agents.
    Step Therapy

    Required prior therapy for certain oncology agents

    Some oncology and hematology agents require prior trials of listed systemic regimens or conventional treatments; providers must document prior regimen history as specified (examples: Imatinib‑related indications or GVHD requirements).

    • Attach prior chemotherapy or regimen details and dates; include mutation/test results when required.
    Step Therapy

    Required prior therapies

    Several oncology/hematology agents require trial of specified therapies (e.g., Jakafi requires prior hydroxyurea or peginterferon in certain PV patients); providers must document prior therapies and any applicable exceptions.

    • Provide prior therapy names, durations, and documented intolerance if applicable.
    Step Therapy

    Step therapy requirement for Ocrevus

    For Ocrevus in relapsing MS, step therapy requires trial of generic dimethyl fumarate (or specified alternatives such as Tecfidera, Bafiertam, Vumerity) prior to approval for patients new to therapy unless other prior therapies permit bypass; document the trial or qualifying exception.

    • If a biologic or alternative listed agent was previously tried (e.g., Copaxone, Lemtrada, Tysabri, Kesimpta), document dates to support bypass.
    Step Therapy

    Otezla step therapy

    Otezla requires a trial of at least one traditional systemic agent (e.g., methotrexate, cyclosporine, acitretin, PUVA) for at least 3 months for plaque psoriasis initial therapy unless the patient is intolerant; a prior biologic counts as a trial.

    • Document prior systemic agent trial duration or intolerance; include prescriber specialty consultation when indicated.
    Step Therapy

    Metyrosine step therapy

    Metyrosine initial therapy requires prior trial of a selective alpha blocker (e.g., doxazosin, terazosin, prazosin); continuation approves if patient is currently receiving or previously received metyrosine.

    • Document trial of a selective alpha blocker and prescriber consultation with an endocrinologist or pheochromocytoma specialist.
    Step Therapy

    Step therapy and prior medication trials

    Step therapy and prior medication trials apply in some situations (examples: chronic antibiotic‑dependent pouchitis requires trials of long‑term ciprofloxacin and metronidazole of at least 4 weeks each prior to Xifaxan approval).

    • Provide documentation of prior long‑term antibiotic trials and recurrence pattern (e.g., ≥3 pouchitis episodes in 12 months).
    Documentation Required

    Required documentation

    Providers must submit required medical information with prior authorization requests including diagnosis, concurrent medications, and previous drugs tried; missing required clinical information (diagnosis, lab, or mutation status) may lead to denial.

    • Include lab/genetic test results, prescriber specialty notes, and prior therapy details as specified by the product criteria.
    • Examples of missing information that trigger denial: absent BRAF V600 status for BRAF‑dependent agents.
    Documentation Required

    Right-heart catheterization requirement

    For PAH WHO Group 1 agents (e.g., ambrisentan/bosentan), prior authorization requires results of right‑heart catheterization to confirm the diagnosis; include the right‑heart catheterization report in the submission.

    • Prescriber must be a cardiologist or pulmonologist or include their consultation note.
    Documentation Required

    HAE confirmation / response documentation

    For Haegarda continuation, the prescriber must confirm the patient has had a favorable clinical response since initiating prophylactic therapy; baseline diagnostic labs for HAE (functional C1‑INH <50% and low serum C4) must be documented when applicable.

    • Submit baseline functional C1‑INH and serum C4 results and a prescriber statement documenting favorable clinical response compared with baseline.
    Documentation Required

    Required Documentation

    Providers must include diagnosis, prior medication history (including the specific therapies tried), and relevant lab or genetic test results or objective measures (e.g., serum ferritin, BCR‑ABL mutation, blood eosinophil counts, biopsy results) when required by the product criteria.

    • Attach objective test reports (imaging, lab values) and notes documenting responses to prior therapies.
    • Failure to supply these documents may delay or result in denial.
    Documentation Required

    Required diagnostic testing

    Fabrazyme prior authorization requires laboratory evidence of deficient alpha‑galactosidase A activity in leukocytes or fibroblasts OR a molecular genetic test demonstrating pathogenic mutations in the galactosidase alpha gene; include the laboratory or genetic report.

    • Prescriber should be a geneticist, endocrinologist, metabolic disorder subspecialist, or physician who treats lysosomal storage disorders.
    Documentation Required

    General documentation

    General documentation expectations: submit diagnosis and prescriber specialty for PA; many products also require objective test results, mutation reports, prior therapy history, and documentation of response for continuation requests.

    • When specialist prescribing is required, include the consultation note or provider specialty credentials.
    • For continuation authorizations, include evidence of clinical benefit as specified by the product entry.
    Denial Risk

    Concurrent biologic/tsDMARD exclusion

    Concurrent use of a Biologic DMARD or a Targeted Synthetic DMARD with the requested agent is an exclusion and may trigger denial; providers must not submit PA requests requesting concurrent biologic/tsDMARD use unless an exclusion exception is documented.

    • Specific examples: Cosentyx, Otezla, Inflectra, Benlysta and others list concurrent biologic or targeted synthetic DMARD use as an exclusion.
    • If concurrent therapy is medically necessary, provide explicit justification and supporting documentation; otherwise request will likely be denied.
    Denial Risk

    Concurrent biologic/tsDMARD exclusion (Cosentyx)

    Cosentyx requests with concurrent use of other biologic therapies or targeted synthetic DMARDs will be denied; ensure no concurrent biologic/tsDMARD is being used when submitting PA for Cosentyx.

    • If prior biologic was used as a step‑trial, document dates and rationale; but concurrent ongoing biologic use is an exclusion.
    Denial Risk

    Concurrent biologic exclusion (Benlysta)

    Benlysta prior authorization has an exclusion risk for concurrent use with other biologics or with Lupkynis; PA requests showing concurrent biologic use without exception may be denied.

    • Ensure Benlysta is being used concurrently only with standard non‑biologic therapies (antimalarials, corticosteroids, immunosuppressants) unless intolerance is documented.
    Note
    Note
    Note
    Prescriber
    Prescribed by or in consultation with rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist
    HAE due to C1-INH deficiency — diagnostic confirmation
    HAE diagnostic confirmationHAE Type I/II: baseline functional C1‑INH <50% of normal AND low serum C4
    Continuation evidenceFor prophylaxis (e.g., Haegarda) prescriber must document favorable clinical response compared with baseline
    Continuation therapy / Continuation criteria
    Continuation requirementOngoing authorization contingent on documented clinical benefit or response to therapy
    Authorization lengthApprovals commonly authorized through the end of the plan year or for 1 year
    DocumentationPrescriber must submit diagnosis, prior medication history, and relevant lab/genetic test results as specified per agent
    EoE diagnostic requirement — biopsy and exclusions
    EoE diagnostic biopsy thresholdEndoscopic biopsy demonstrating >=15 intraepithelial eosinophils per high‑power field
    Other requirementsExclude secondary causes and complete an Rx‑strength PPI trial for ≥8 weeks before initiation
    EGPA — contextual reference for eosinophil criteria
    EGPA referenceEosinophilic granulomatosis with polyangiitis (EGPA) cited for eosinophil and prescriber criteria
    PrescriberFor EGPA, prescriber consultation may include rheumatologist or pulmonologist as listed
    Hereditary Angioedema diagnostic confirmation — labs and thresholds
    HAE diagnostic lab confirmationBaseline functional C1‑INH <50% of normal and low serum C4 required
    Use for acute treatmentIcatibant initial therapy requires these baseline lab confirmations for HAE Type I/II
    BRAF V600 mutation — molecular requirement
    BRAF V600 mutationSpecific activating mutation in BRAF (codon V600) required for BRAF/MEK inhibitor indications
    Testing requirementDocument BRAF V600 mutation status from an approved test for therapy eligibility
    KRAS G12C mutation — molecular requirement
    KRAS G12C mutationKRAS G12C activating mutation required for Lumakras (sotorasib) indications
    Prior therapyOften requires prior systemic regimen(s) per indication (e.g., NSCLC after ≥1 regimen)
    Part B Prerequisite — administrative note
    Part B prerequisite flagIndicates whether a Part B versus Part D determination applies at PA review per CMS guidance
    ExampleSome oncology products note Part B prerequisite at prior authorization (see individual product entries)
    Uncontrolled asthma criteria (examples for Xolair)
    Uncontrolled asthma examples (Xolair)Includes baseline IgE >=30 IU/mL, positive allergy testing to relevant aeroallergens, ≥3 months ICS plus another controller, and uncontrolled symptoms or exacerbations as defined in policy
    Role in PAThese criteria are used to determine Xolair eligibility and continuation response